| ²é¿´: 1091 | »Ø¸´: 24 | |||
[½»Á÷]
´Ó¾µäÀýÎÄÖÐѧϰӢÎÄÂÛÎÄд×÷£¨µÚ1ÆÚ£ºSemaglutide£©
|
|||
|
´ó¼ÒºÃ£¬ÎÒÊÇÒ½Ò©ÐÐÒµµÄÒ»Ãû´ÓÒµÈËÔ±£¬ÒµÓàʱ¼ä»á´ÓÊÂһЩרҵ·Òë·½ÃæµÄ¹¤×÷£¬¶Ï¶ÏÐøÐøÓм¸Äêʱ¼äÁË¡£ Æäʵ·Òë²¢²»ÉñÃØ£¬×îÖØÒªÖ®´¦ÎÞ·ÇÊǶàÁ·¶à¿´£¬´ÓºÃµÄÎÄÕÂÖÐÌáÈ¡×îµØµÀµÄ±í´ï£¬ÈÚÈëµ½×Ô¼ºµÄ±í´ïÖ®ÖС£Òò´Ë£¬ÎÒ×ÜÊÇ»á³é³öºÜ¶àʱ¼ä½øÐÐһЩ·ÒëµÄÁ·Ï°À´ÌáÉý×Ô¼º¡£ ÔÚ×öÁ·Ï°µÄʱ£¬ÎÒÓÐÒ»ÌìÏëµ½£¬¼ÈÈ»ÒѾ×öÁËһЩ¹¤×÷£¬ÄÇôΪºÎ²»Í¬Ê±°ÑÕâЩ¹¤×÷ÄÚÈÝ·ÖÏí³öÀ´ÄØ¡£Ò»·½Ãæ¿ÉÒÔ°ïÖúÓÐÐèÇóµÄС»ï°é×ÔÎÒÌáÉý£¬Ò»·½ÃæÊÕµ½±ðÈ˵ãÆÀºÍÌáÎʶÔ×Ô¼ºÒ²ÊÇÒ»ÖÖÊÕ»ñ¡££¨ÔÚÕâÀï¸Ðл³ÂÊýÑòǰ±²¸øÎҵĴøÀ´µÄÆô·¢¡£ÁíÍ⣬±¾ÆªÎÄÕÂÖеĺܶàÄÚÈÝÒ²À´×ÔÊýÑòÀÏʦµÄ½Ìѧ·ÖÏí£©¡£ ÎÒ×öÁ·Ï°µÄ·½Ê½ÊǷdz£¡°±¿¡±µÄ£¬»áÏȰÑÎÄÕ·Òë³ÉÖÐÎÄ£¬ÔÙ×Ô¼º·Òë»ØÈ¥¶ÔÕÕÔÎĽøÐÐѧϰ¡£±¾ÎĵĻطͳһÓÃÁË»úÆ÷·Ò룬ËäÈ»ÔÚ×Ô¼º×öÁ·Ï°Ê±²»½¨ÒéÕâÑù×ö¡£ÁíÍâÏë˵һÏ£¬ÔÚ´ó¼Òд×÷¹ý³ÌÖл¹ÊǷdz£½¨ÒéÄÜÒÔ»úÆ÷·Òë½á¹û×÷Ϊ²Î¿¼µÄ£¬ÒòΪÏÖÔڵĻúÆ÷·ÒëˮƽÒѾ±È½ÏÎȶ¨ºÍÓÅÐãÁË£¬Õ¾ÔÚËüµÄ¼ç°òÉÏ£¬¶ÔÂÛÎÄд×÷Óкܴó°ïÖú¡£ÄÇôÎÒÃÇÐèҪѧϰµÄÆäʵÊÇ£¬ÈçºÎÔÚ»úÆ÷·ÒëÉϽøÒ»²½µÄÌá¸ß×Ô¼º¡£ ½ñÌìÒª·ÖÏíµÄһƪÎÄÕ½ÚÑ¡×Ô˾ÃÀ¸ñ³ëĵÄÁÙ´²ÊÔÑéÂÛÎÄ£ºTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial¡£ ˾ÃÀ¸ñ³ëÄ£¨semaglutide£©Êǵ¤ÂóŵºÍŵµÂ¹«Ë¾£¨Novo Nordisk£©ÕâÁ½Äê´ó»ðµÄ²úÆ·£¬Ö÷Òª×÷ÓÃÊÇ´Ù½øÒȵºËØ·ÖÃÚ¡£ÒȵºËØ¿ÉÒÔ½µµÍѪÌÇ£¬ÓÃÓÚÖÎÁÆÌÇÄò²¡£¬Ò²¿ÉÒÔÓÃÓÚ¼õ·Ê¡£ ¹ØÓÚsemaglutideµÄÁÙ´²ÊÔÑéÊÇһϵÁеģ¬Ä¿Ç°ÒѾÓÐ8¸ö¹ØÓÚsemaglutideµÄÁÙ´²ÊÔÑé½áÊøÇÒ·¢²¼Á˽á¹û£¬Ïà¹ØÎÄÕ»ù±¾¶¼·¢±íÔÚҽѧ¶¥¿¯ÉÏ£¬ÎÒÃÇÒªÌÖÂÛµÄÕâÆªÀ´×ÔNature Medicine¡£ ÄǺóÃæ¾ÍÈÃÎÒÃÇÀ´¿´Ò»¿´ÎÄÕÂÖеÄÕâЩµØµÀ±í´ï°É£¡ £¨ÄúµÄÖ§³ÖºÍ¹ÄÀøÊÇÎÒǰ½øµÄ¶¯Á¦¡£Èç¹ûϲ»¶µÄÅóÓÑÃǶ࣬ÎÒºóÐø»á³ÖÐø¸üв»Í¬µÄÄÚÈÝ¡£ÄúÈç¹ûÓбȽϺõÄÏëÒªÒ»ÆðÔĶÁѧϰµÄÎÄÕ£¬Ò²¿ÉÒÔ¸æËßÎÒ£¬ÎÒÃÇÒ»Æðѧϰ½ø²½¡£ÓÉÓÚÆª·ùÔÒò£¬×îºÃÊÇÊÔÑéÀàÎÄÕ²»ÒªÊÇ×ÛÊöŶ¡££© |
» ²ÂÄãϲ»¶
¡¾Çóµ÷¼Á¡¿085601²ÄÁϹ¤³Ìר˶ | ×Ü·Ö272 |
ÒѾÓÐ5È˻ظ´
275Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
0856£¬²ÄÁÏÓ뻯¹¤321·ÖÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
085701»·¾³¹¤³Ì£¬267Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
320·Ö£¬²ÄÁÏÓ뻯¹¤×¨Òµ£¬Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
085701»·¾³¹¤³ÌÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
295²ÄÁϹ¤³Ìר˶Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
265Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
322Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
085602 307·Ö Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
Î人·ÄÖ¯´óÑ§È«ÖØÊµÑéÊÒ¹ú¼Ò¼¶È˲ÅÍŶÓÏȽøÏËάÓ빦ÄÜÆ÷¼þ¿ÎÌâ×é ½ÓÊÕµ÷¼ÁÑо¿Éú
+1/56
2026ÑÓ°²´óѧÉèÊ©Ê߲˻·¾³µ÷¿ØÓë·Ö×Ó»úÖÆÑо¿ÍŶÓÍŶÓÕÐÊÕÏà¹Ø×¨Òµµ÷¼ÁÑо¿Éú
+1/45
¹ã¶«Î¨Ò»Ê¯»¯ÔºÐ£¡ª¡ª×ÊÔ´Óë»·¾³×¨Ë¶ÕÐÉú
+1/42
ÖйúʯÓÍ´óѧ£¨±±¾©£©¹ú¼Ò¼¶´óÈ˲ÅÍŶӲ©Ê¿ÕÐÉú1Ãû£º»¯Ñ§¡¢²ÄÁÏ¡¢Ê¯Ó͹¤³Ì£ºÓÍÌﻯѧ
+1/38
»·¾³»¯Ñ§¡¢µØÑ§¡¢»·¾³¶¾Àí·½Ïò£¬Éó¤ÎÛȾÎïÇ¨ÒÆ×ª»¯½µ½â¡¢·ÖÎö¼ì²â¡¢¼ÆËãÄ£ÄâÕßÓÅÏÈ
+1/34
ÕÐÊÕ²ÄÁÏ¡¢»¯Ñ§Ààµ÷¼ÁÉú£¬×¨Ë¶Ñ§Ë¶¾ù¿É
+1/33
¸£½¨Ê¦·¶´óѧ»·¾³Óë×ÊԴѧԺ»·¾³µç»¯Ñ§¿ÎÌâ×éÕÐÊÕ2026˶ʿ£¨º¬µ÷¼Á£©
+1/29
˫һÁ÷ÏæÌ¶´óѧ»¯¹¤Ñ§ÔºÕÐÊÕ»¯¹¤¡¢ÄÜÔ´¶¯Á¦¡¢¹¤³ÌÈÈÎïÀíÏà¹ØÑо¿Éúµ÷¼Á
+1/14
Õã½´óѧ¹âµçѧԺ¡¢¼«¶Ë¹âѧʵÑéÊÒ °¢Ãë·½Ïò ÕÐÆ¸¿ÆÑÐÖúÀí2Ãû
+1/13
ÖйúµØÕð¾ÖµØÖÊÑо¿Ëù+µØÇòÎïÀíרҵ+½ÓÊÕµ÷¼Á
+1/11
³ÏƸ²©Ê¿¿ÆÑÐÈËÔ±£¨ÓлúºÏ³É»¯Ñ§·½Ïò£©
+1/10
¡¾²©Ê¿ÕÐÉú¡¿Ìì½òÀí¹¤´óѧ¹ú¼Ò½ÜÇàÍõÌú¿ÎÌâ×éÕÐÊÕ2026Ä격ʿÑо¿Éú
+1/9
ÄÏ¿ª´óѧ»·¾³¿ÆÑ§Ó빤³ÌѧԺÍõöνÌÊÚ¿ÎÌâ×éÕÐÊÕÉêÇ뿼ºËÖÆ²©Ê¿Éú
+1/9
¡î ¡î ÖÐɽ´óѧ¸½ÊôµÚÆßÒ½ÔºÐ¤ÜÆ½à¿ÎÌâ×é³ÏÕзÖ×Óҽѧ·½Ïò˶ʿÉú£¨µ÷¼ÁÉú£© ¡î ¡î
+1/8
ÄϾ©ÁÖÒµ´óѧ»¯Ñ§¹¤³ÌѧԺ°ØÐÊ·å¿ÎÌâ×éÕÐÊÕ˶ʿÑо¿Éú1Ãû
+1/6
Î人·ÄÖ¯´óѧȫ¹úÖØµãʵÑéÊÒÂÀÓÀ¸Ö½ÌÊÚ¿ÎÌâ×éÕÐÊÕ²ÄÁÏ¡¢»¯Ñ§¡¢ÉúÎïÏà¹Ø×¨ÒµË¶Ê¿Ñо¿Éú
+1/5
Ìì½ò¹¤Òµ´óѧ˫һÁ÷¸ßУÕв©Ê¿¡¢Ë¶Ê¿¡¢²©Ê¿ºó
+1/4
ÕÐÊÕ´ÓÊÂ´óÆø¸´ºÏÎÛȾ³ÉÒòÁìÓòÑо¿Éú
+1/3
Ó¢¹ú½£Çź÷¿³ö×â
+1/3
ÏæÌ¶´óѧ½ÌʦÕÐÆ¸
+1/1
|
Main²¿·Ö °üÀ¨¸Ä±äÒûʳºÍÉíÌå»î¶¯µÄÐÐΪ¸ÉÔ¤ÈÔÈ»ÊÇÖÎÁƳ¬ÖغͷÊÅֵĻù´¡¡£ ÔÎÄ£ºBehavioral intervention incorporating modifications in diet and physical activity remains the foundation of treatment for overweight and obesity. ÒëÎÄ£ºBehavioral intervention combined with diet change and physical activity is still the basis for the treatment of overweight and obesity. 1. "incorporating" Ç¿µ÷ÕûºÏ»òºÏ²¢£¬Ê¹Ä³Îï³ÉΪÕûÌåµÄÒ»²¿·Ö£¬ÓÐÄÉÈëµÄÒâ˼£¬¶ø "combined with" ¸ü¶àµØÃèÊöÁ½¸ö»ò¶à¸öÔªËØÏ໥½áºÏ£¬"including" ¸ü¶àµØ±íʾÁоٻò¼òµ¥µØÌí¼ÓÄ³Ð©ÔªËØ£¬¶ø²»Ò»¶¨ÒªÓëÆäËû²¿·Ö½ôÃܽáºÏ¡£Õ⼸¸ö´Ê¶¼¿ÉÒÔ·ÒëΪ°üÀ¨£¬½áºÏ¡£Èç¹ûÊdzöÏÖÔÚҽѧ²©Ê¿¿¼ÊÔÖУ¬ÄÇ´ó¸ÅÂÊ»áÔÚÑ¡ÔñÌâÖÐÑ¡ÔñÒ»¸öÌæ»»´Ê£¬±ÈÈçinclude¡£Á½ÕßÊǽüÒå´Ê£¬²»¹ýincorporateÓиüÃ÷ÏԵġ°ÄÉÈ롱Òâ˼£¬¶øinclude¾ÍÖ»ÊÇ¡°°üº¬¡±¡£±ÈÈçÔÚÕâ¾ä»°ÖУ¬ÐÐΪ¸ÉÔ¤¡°ÄÉÈ롱ÁËÒûʳºÍ»î¶¯³ÉΪһ¸öÕûÌ壬ÔÚ¾ßÌå±í´ïʱ¿ÉÒÔÖ±½Ó·ÒëΪ¡°°üº¬/°üÀ¨¡±¡£ 2. "modifications in" ÍùÍùÃèÊö΢СµÄµ÷Õû£¬¶ø "change" ÊÇÒ»¸ö¸üΪÆÕ±éµÄÊõÓÓÃÓÚÃèÊö´Ó΢Сµ½ÏÔÖøµÄÈκα仯»òת±ä¡£¿ÉÒÔ»¥ÏàÌæ»»¡£ 3. "remains"ºÍ"is still"ÕâÁ½¸ö¶ÌÓﶼǿµ÷ijÖÖ״̬»òÇé¿öµÄ³ÖÐøÐÔ¡£µ«"remains" ÓÐʱ¸øÈËÒ»ÖÖÉÔ΢ÕýʽµÄ¸Ð¾õ£¬¶ø "is still" ÔÚÈÕ³£¶Ô»°ÖпÉÄܸüΪ³£¼û¡£¿ÉÒÔ»¥ÏàÌæ»»¡£ 4. "foundation" ͨ³£Ç¿µ÷ijʵĺËÐÄÔÔò£¬ÓлùʯµÄº¬Ò壬¶ø "basis" ÔòÇ¿µ÷Âß¼¡¢ÔÒò»òÖ¤¾Ý¡£Ò²¿ÉÒÔ»¥ÏàÌæ»»¡£ È»¶ø£¬ÓÉÓÚÐÐΪ¸ÉԤͨ³£ÓëÁÙ´²ÉÏÓÐÒâÒåºÍ¿É³ÖÐøµÄÌåÖØ¼õÇáÎ޹أ¬Òò´Ë½¨Ò齫ҩÎïÖÎÁÆ×÷ΪÌåÖØÖ¸Êý£¨BMI£©ÖÁÉÙΪ 30 kg m-2 »ò»¼ÓÐÌåÖØÏà¹Ø¹²²¡Ö¢ÖÁÉÙΪ 27 kg m-2 µÄÈËȺ³¤ÆÚÌåÖØ¹ÜÀíµÄ¶îÍâÊֶΡ£ ÔÎÄ£ºHowever, because behavioral intervention is often not associated with clinically meaningful and sustainable weight loss, pharmacotherapy is recommended as an additional tool for long-term weight management in people with a body mass index (BMI) of at least 30 kg m¨C2, or at least 27 kg m¨C2 in those with weight-related comorbidities. ÒëÎÄ£ºHowever, since behavioral interventions are usually not associated with clinically meaningful and sustainable weight loss, it is recommended that drug therapy be used as an additional tool for long-term weight management of people with a body mass index (BMI) of at least 30 kgm-2 or with weight related comorbidities of at least 27 kgm-2. 1. "because" ¸üÖ±½Ó£¬¶ø "since" ÔòÓÐÒ»ÖÖ»ùÓÚÒÑÖª»ò¹«ÈÏÊÂʵµÄº¬Òå¡£Á½ÕßÔÚ´Ë¿ÉÒÔ»¥»»¡£ 2. ÁíÍâѧϰһÏ¡°it is recommended that ¡ be used as ¡¡± ¿ÉÒÔд³É ¡°¡ is recommended as ¡¡± 3. ÓÐͳ¼ÆÑ§ÒâÒåµÄ¡°ÒâÒ塱Óà significant/significance »ù±¾ÊÇÔ¼¶¨Ë׳ɵÄÓ÷¨£¬µ«ÓÐÁÙ´²ÒâÒåµÄ¡°ÒâÒ塱ӢÓïÓôʻ¹²»ÄÇôͳһ£¬¿ÉÒÔ¼ûµ½Óà significant/significance¡¢meaningful/meaningfulness¡¢important/importance µÈ¡£Í¬Ê±£¬clinically/clinical »¹¿ÉÓà practically/practical »òÕß medically/medical µÈ¡£ 4. Ò©ÎïÁÆ·¨/ÖÎÁÆÒ»°ã¿ÉÄܱȽÏÏëµ½µÄ±í´ïÊÇdrug treatment/therapy£¬Ò²¿ÉÒÔÓÃpharmacotherapyÌæ»»¡£ÔÚ±íʾ¡°½¨Ò顱µÄʱºò£¬Ò»°ãÎÒÃÇ»áÏëµ½adviceºÍsuggest£¬µ«ºÜ¶àʱºòÎÒÃÇÒ²¿ÉÒÔÓÃrecommendÍÆ¼öÌæ»»£¬¶øÇÒ´Ó˵»°×Ë̬ÉϸüƽµÈһЩ¡£ 5. as an additional tool£¬Õâ¸ö±í´ïÒ²¼Çһϣ¬ÖÐÎij£Óöµ½¡°×÷Ϊ¡¡²¹³ä/ÆäËûXX·½·¨/ÊֶΡ±£¬ÎÒÃǵ±È»¿ÉÒÔÓÃas a complementary/supplementary XX method/approach£¬Ò²¿ÉÒÔÓÃadditional tool¡£ Semaglutide ÊÇÒ»ÖÖÒȸßѪÌÇËØÑùëÄ-1£¨GLP-1£©ÀàËÆÎ±»Åú×¼ÓÃÓÚÖÎÁƶþÐÍÌÇÄò²¡£¨¿Ú·þ Semaglutide ºÍƤÏÂ×¢Éä Semaglutide£©ºÍ½µµÍ¶þÐÍÌÇÄò²¡ºÍÐÄѪ¹Ü¼²²¡»¼ÕßµÄÐÄѪ¹Üʼþ·çÏÕ£¨½öƤÏÂ×¢Éä Semaglutide£©¡£ ÔÎÄ£ºSemaglutide is a glucagon-like peptide-1 (GLP-1) analog approved for the treatment of type 2 diabetes (oral semaglutide and subcutaneous semaglutide) and for reducing the risk of cardiovascular events in people with type 2 diabetes and cardiovascular disease (subcutaneous semaglutide only). ÒëÎÄ£ºSemaglutide is a glucagon like peptide-1 (GLP-1) analog, which is approved for the treatment of type 2 diabetes mellitus (oral semaglutide and subcutaneous semaglutide) and reducing the risk of cardiovascular events in patients with type 2 diabetes mellitus and cardiovascular disease (subcutaneous semaglutide only). 1. Õâ¶Î·ÒëµÄ·Ç³£ºÃ£¬Ö»ÊÇ approved for ÈçÊ¡ÂÔ which is ¿ÉÂÔÏÔ¼ò½à¡£Ò½Ñ§ÀàÂÛÎÄ/²úÆ·Ñо¿Öо³£³öÏÖFDA approvedºÍFDA cleared£¬ËüÃÇÁ½¸öÓÐÊ²Ã´Çø±ðÄØ£¿approved±ÈclearedÒªÇó¸ü¸ß£¬±ÈÈçÔÚÒ©ÎïÉÏ£¬±ØÐëÒªÖ¤Ã÷°²È«ÐÔºÍÓÐЧÐÔ£¬²Å¿ÉÒÔapproved£¬approvedºóµÄ²úÆ·Ò²Òâζ×Å»ñÒæ±ÈÒÑÖª·çÏÕ´ó¡£¶øclearedÒ»°ãÊÊÓÃÓÚ¸úÏÖÓвúÆ·ÏàËÆµÄвúÆ·£¬¶ø²»Ò»¶¨ÊÇͨ¹ýÁ˶ÀÁ¢µÄ°²È«ÐÔÊÔÑ顣˵µ½ÕâÀÓÐʱºò¿ÉÄÜ»¹»á¿´µ½FDA registeredºÍFDA certificated£¬ÕâÁ½¸ö±í´ï¸úFDAµÄÈÏ¿ÉûÓÐʲô¹ØÏµ£¬Èç¹ûij¸ö²úÆ·ÓÃÁËÕâЩ±í´ïÐû´«£¬ÄÇ´ó¸ÅÂʾÍÊÇÉú²úÉÌÒªÆÈËÁË¡£ ¸ù¾Ý semaglutide ¶Ô·ÊÅÖ»¼ÕßµÄÖÎÁÆÐ§¹û£¨STEP£©ÁÙ´²ÊÔÑ鼯»®µÄ½á¹û£¬ÃÀ¹ú¡¢Å·ÖÞ¡¢Ó¢¹úºÍ¼ÓÄôóÅú׼ƤÏÂ×¢Éä semaglutide£¬¼ÁÁ¿Îª2.4 mg£¬Ã¿ÖÜÒ»´Î£¬ÓÃÓÚ³¬ÖØ£¨BMI¡Ý27 kg m-2£¬ÖÁÉÙÓÐÒ»ÖÖÌåÖØÏà¹Ø¹²²¡Ö¢£©»ò·ÊÅÖ£¨BMI¡Ý30 kg m-2£©µÄ³ÉÈ˵ÄÌåÖØ¹ÜÀí¡£ ÔÎÄ£ºAt a dose of 2.4 mg once-weekly, subcutaneous semaglutide was approved in the United States, Europe, the United Kingdom and Canada for weight management in adults with overweight (BMI ¡Ý 27 kg m¨C2 with at least one weight-related comorbidity) or obesity (BMI ¡Ý 30 kg m¨C2), based on results from the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial program. ÒëÎÄ£ºAccording to the results of the treatment effect of semaglutide on obese patients (step) clinical trial plan, the United States, Europe, the United Kingdom and Canada approved the subcutaneous injection of semaglutide at a dose of 2.4 mg once a week for the weight management of overweight (BMI ¡Ý 27 kgm-2, at least one weight related comorbidity) or obese (BMI ¡Ý 30 kgm-2) adults. 1. Õâ¾ä»°Óôʶ¼Ã»ÓÐʲôÎÊÌ⣬µ«ÊÇ·¸ÁË»úÆ÷·ÒëºÍ²»ÉÙˮƽ²»´íÒëÕß·ÒëÖÐ×î³£¼ûµÄ벡£¬ÄǾÍÊǽé´Ê¶ÌÓï±È½Ï¶àµÄʱºòÅÅÐòϰ¹ß»¹Êǰ´ÕÕÖÐÎĵÄÀ´£¬Ïà¶ÔÖØÒªµÄ²¿·Ö·ÅµÄÌ«¿¿ºóÁË£¬Òò´Ë·ÒëÏÂÀ´´øÓÐŨŨµÄÖÐʽӢÓï·ç¸ñ£¬ÁíÍâÖ÷Òª½á¹¹Ò²Ã»ÓÐÓøü·ûºÏÓ¢Óï±í´ïϰ¹ßµÄ±»¶¯Óï̬¡£Õâ¾ä»°Óа˸ö½é´Ê¶ÌÓAt a dose of 2.4 mg once-weekly£¬in the United States¡£¬in adults£¬with overweight£¬with at least one weight-related comorbidity£¬or obesity£¬based on results£¬from the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial program£¬Ò»¶¨Òª¶à¶àÕå×ã¬ÊìϤÆäÅÅÐòµÄÓ¢Óï±í´ïϰ¹ß¡£ 2. managementÒ²¿ÉÒÔ¶à¹Ø×¢Ò»Ï£¬ÓÐʱºò¿ÉÒÔÌæ»»control£¬±ÈÈçѪѹ¿ØÖÆ blood pressure control£¬Ò²¿ÉÒÔ»»´Êblood pressure management¡£ ÔÚûÓÐ 2 ÐÍÌÇÄò²¡µÄ²ÎÓëÕßµÄ STEP 1 ºÍ 3 ÊÔÑéÖУ¬Ê¹Óà semaglutide 2.4 mg ¹Û²ìµ½Æ½¾ù¼õÈ¥°²Î¿¼ÁµÄÌåÖØ¼õÇáÔÚ 68 ÖÜ·Ö±ðΪ 12.4% ºÍ 10.3% ¡£ ÔÎÄ£ºIn the STEP 1 and 3 trials in participants without type 2 diabetes, average placebo-subtracted weight losses of 12.4% and 10.3%, respectively, were seen with semaglutide 2.4 mg at week 68. ÒëÎÄ£ºIn the STEP 1 and 3 trials of participants without type 2 diabetes, using semaglutide 2.4 mg, we observed that the average weight loss after subtracting placebo was 12.4% and 10.3% at 68 weeks, respectively. 1. Õâ¾ä»°ÓÖÊÇÒ»¸öºÜºÃµÄ·¶Àý£¬±í´ïÉÏËäȻûʲôÎÊÌ⣬µ«ÊDZí´ï´øÓÐō֨µÄÖÐÎÄϰ¹ß¡£×¢Ò⣬Óñ»¶¯Óï̬°ÑÒª±í´ïµÄÖØµãÌáǰ£¡ 2. "seen"Ö÷ÒªÓë¼òµ¥µÄÊÓ¾õ¸ÐÖªÓйأ¬¶ø "observed" ³ýÁ˱íʾ¿´µ½Í⣬»¹´øÓиüÉîÈë¡¢×Ðϸ»òרҵµÄ¹Û²ìµÄº¬Òå¡£Õâ¾ä»°²Î¿¼ÒëÎĵÄÓôʱíÏÖÉõÖÁ¸üºÃһЩ¡£ STEP ÊÔÑéÏîÄ¿ÖÐÏÈǰµÄÑо¿½öÏÞÓÚ³¤´ï 68 ÖܵÄÖÎÁƳÖÐøÊ±¼ä¡£ ÔÎÄ£ºPrevious studies in the STEP trial program have been limited to treatment durations of up to 68 weeks. ÒëÎÄ£ºPrevious studies in the STEP trial were limited to treatment duration of up to 68 weeks. 1. Õâ¾ä»°ÓÐÁ½¸ö¹Ø×¢µã£¬Ò»¸öÊÇʱ̬£¬Ò»¸öÊǵ¥¸´Êý¡£Èç¹ûÓÃÏÖÔÚÍê³Éʱ£¬±íʾ STEP Ñо¿»¹ÔÚ¼ÌÐø£¬Ã»ÓнáÊø¡£Óùýȥʽ±íʾ STEP Ñо¿ÒѾÍê³É¡£ÕâÀïҪעÒâÇø·Öһϵ½µ×ÐèÒªÓÃÄÄÖÖʱ̬±í´ï¡£ÁíÍâÎÄÖÐÓÃÁË up to Òâ˼Ϊ×î¸ß´ïµ½£¬²»Í¬ÊÔÑéµÄ treatment duration ÊDz»Í¬µÄ£¬ÕâÀïÓ¦¸ÃÓø´Êý¡£ ±¾Îı¨µÀµÄ STEP 5 Ñо¿ÎªÆÚ 2 Äּ꣬ÔÚÆÀ¹ÀÿÖÜÒ»´ÎƤÏÂ×¢Éä 2.4 mg semaglutide Ó밲ο¼ÁÏà±È£¬×÷ΪÐÐΪ¸ÉÔ¤µÄ¸¨ÖúÊֶΣ¬Õë¶Ô·ÊÅÖ£¨BMI ¡Ý 30 kg/m² £©³ÉÄêÈË£¬»ò³¬ÖØ£¨BMI ¡Ý 27 kg/m² £©³ÉÄêÈË£¬ÇÒÖÁÉÙ´æÔÚÒ»ÖÖÓëÌåÖØÏà¹ØµÄ¹²²¡Ö¢ÇÒûÓÐÌÇÄò²¡£¬¶ÔÌåÖØºÍÐÄѪ¹Ü´úл·çÏÕÒòËØµÄ³¤ÆÚÓ°Ïì¡£ ÔÎÄ£ºThe 2-year STEP 5 study reported herein was conducted to evaluate the long-term effect of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo, as an adjunct to behavioral intervention, on body weight and cardiometabolic risk factors, in adults with obesity (BMI ¡Ý 30 kg m¨C2), or with overweight (BMI ¡Ý 27 kg m¨C2) and at least one weight-related comorbidity, without diabetes . ÒëÎÄ£ºThe 2-year step 5 study reported in this paper aims to evaluate the long-term impact of weekly subcutaneous injection of 2.4 mg semaglutide on weight and cardiovascular metabolic risk factors in obese (BMI ¡Ý 30 kg/M ² or overweight (BMI ¡Ý 27 kg/m ² ) adults with at least one weight related comorbidity and no diabetes compared with placebo.1. ѧϰһÏ herein µÄʹÓ㬿ÉÒÔ´úÌæ here£¬in this paper£¬in this study µÈ±í´ï¡£ÔÎÄÔÚÕâ¶Î»°µÄ´¦ÀíÉϸü¼ò½à£¬ÊÇÎÒÃÇÐèҪѧϰµÄµØ·½¡£ 2. "was conducted to" ÃèÊöÁËÒѾ·¢ÉúµÄÊÂÇéµÄÄ¿µÄ£¬¶ø "aims to" ÃèÊöÁËÏÖÔÚ»òδÀ´µÄ¼Æ»®»ò»î¶¯µÄÄ¿±ê¡£¹ýȥʱ̬µÄ±»¶¯Óï̬¸ü·ûºÏÎÄÕÂÒâ˼ºÍÓ¢Óïϰ¹ß¡£ 3. Cardiometabolic Óë cardiovascular metabolic£¬¾¹ý²éÖ¤£¬ºóÕ߸ü³£¼ûһЩ£¬µ«Ç°ÕßÊÇÒ»¸öרÓÐÃû´Ê¡£Òò´ËÔÚ×öרҵ´Ê»ã²éÖ¤µÄʱºòÐèÒª×Ðϸ¡£ 4. "impact" ÍùÍù´øÓиüÇ¿ÁÒ»ò¸üÖ±½ÓµÄÓ°ÏìµÄº¬Ò壬¶ø "effect" ¸üΪÖÐÐÔ£¬Ö¸µÄÊÇij¸öÔÒòµÄÖ±½Ó½á¹û»òºó¹û¡£ÔÚÕâÀïµÄÓ°ÏìÓà effect ¸üºÃЩ£¬¿ÉÒÔÓë±êÌâºôÓ¦¡£ 5. Without ºÍ and no ¶¼¿ÉÒÔÓÃÔÚÕâÀï¡£ 6. Õâ¾ä»°ÓÐÊ®¸ö½é´Ê¶ÌÓï¡£ÒëÎĵıíÏÖ¿ÉÒÔ˵Ï൱²»´í£¬Ö»Ðèµ÷Õûcompared with placebo µÄλÖã¬ÁíÍâ×öһЩ±í´ïÉϵÄС΢µ÷¡£ ÕâÏî3ÆÚ¡¢Ëæ»ú¡¢Ë«Ã¤¡¢°²Î¿¼Á¶ÔÕÕ¡¢¶à¹úÊÔÑé´ú±íÁËÆù½ñΪֹʹÓà semaglutide ½øÐÐÌåÖØ¹ÜÀíµÄ×Ñо¿¡£ ÔÎÄ£ºThis phase 3, randomized, double-blind, placebo-controlled, multinational trial represents the longest study of the use of semaglutide for weight management to date. ÒëÎÄ£ºThis phase 3, randomized, double-blind, placebo-controlled, multinational trial represents the longest study of weight management using semaglutide to date. 1. Õâ¾ä»°±È½Ï¼òµ¥£¬ÒëÎĵÄÍê³É¶ÈºÜ¸ß¡£to dateѧϰһÏ£¬¡°½ØÖ¹µ½Ä¿Ç°¡±¡£ 2. Õâ¾ä»°Ö»ÓÐÒ»µãС覴㬾ÍÊÇÒª°ÑÖØµã¡°Ê¹Óà semaglutide ½øÐС±·ÅÔÚǰ±ß¡£ÕâÑù¾ÍºÍÔÎÄÍêȫһÖÂÁË¡£ ¹²Í¬Ö÷ÒªÖÕµãÊÇ´Ó»ùÏßµ½µÚ 104 ÖÜÌåÖØµÄ°Ù·Ö±È±ä»¯£¬ÒÔ¼°ÔÚµÚ 104 ÖÜÌåÖØ¼õÇá³Ì¶ÈÖÁÉÙΪ»ùÏßÌåÖØµÄ 5%¡£ ÔÎÄ£ºCo-primary endpoints were percentage change in body weight from baseline to week 104 and achievement of weight loss of at least 5% of baseline weight at week 104. ÒëÎÄ£ºThe common primary endpoint was the percentage change in body weight from baseline to week 104 and a weight loss of at least 5% of baseline body weight at week 104. 1. ÒëÎÄÔÚÕâÀï·¸ÁËÒ»¸ö±È½Ï´óµÄ´íÎ󣬹²Í¬Ö÷ÒªÖÕµã Co-primary endpoints ·Òë³ÉÁ˹²Ê¶ÖеÄÖ÷ÒªÖÕµã common primary endpoint¡£ËùÒÔרҵ´Ê»ã×îºÃ·´¸´Ð£¶Ô¡£ 2. ÒëÎĵ¥¸´ÊýÓôíÁË¡£ÓÉÓÚÖÐÎÄϰ¹ß²»Çø·Öµ¥¸´Êý£¬Òò´ËÒëÎÄÖÐÈÝÒ׳ö´í£¬ÐèҪСÐÄ¡£ 3. weight loss ǰ¼ÓÈë achievement ¿ÉÒÔʹ±í´ï¸üµØµÀ£¬ºôÓ¦percentage change in body weight¡£ÔÚÓ¢Îıí´ïʱºòҪѧ»á¼ÓÉÏÕâЩʵ¼Êº¬Òå²»´óµ«È´Ó°ÏìÕûÌå¹Û¸ÐµÄ´Ê»ã¡£ |
21Â¥2023-09-16 17:49:54
7Â¥2023-09-15 21:28:05
ll9999
ר¼Ò¹ËÎÊ (ÎÄ̳¾«Ó¢)
-

ר¼Ò¾Ñé: +584 - SEPI: 2
- Ó¦Öú: 8021 (½ÌÊÚ)
- ¹ó±ö: 60.073
- ½ð±Ò: 290576
- Ìû×Ó: 37510
- ÔÚÏß: 3178.5Сʱ
- ³æºÅ: 1410396
5Â¥2023-09-15 20:53:13
chenhuanlong
½û³æ (ÎÄѧ̩¶·)
¡ï
peoplezz(½ð±Ò+5): лл²ÎÓë
peoplezz(½ð±Ò+5): лл²ÎÓë
|
±¾ÌûÄÚÈݱ»ÆÁ±Î |
10Â¥2023-09-15 22:37:31
11Â¥2023-09-15 22:49:56
liunahan
ľ³æÖ®Íõ (ÎÄѧ̩¶·)
- Ó¦Öú: 118 (¸ßÖÐÉú)
- ½ð±Ò: 136546
- Ìû×Ó: 106919
- ÔÚÏß: 5502.4Сʱ
- ³æºÅ: 260314
19Â¥2023-09-16 14:18:36
24Â¥2023-09-16 21:41:51
¼òµ¥»Ø¸´
´ó½ð×Ó09152Â¥
2023-09-15 19:06
»Ø¸´
tzynew3Â¥
2023-09-15 19:16
»Ø¸´
peoplezz(½ð±Ò+5): лл²ÎÓë
l ·¢×ÔСľ³æAndroid¿Í»§¶Ë
yuekong4Â¥
2023-09-15 20:32
»Ø¸´
hyjcs6Â¥
2023-09-15 21:05
»Ø¸´
peoplezz(½ð±Ò+5): лл²ÎÓë
ภ·¢×ÔСľ³æAndroid¿Í»§¶Ë
psylhh8Â¥
2023-09-15 21:28
»Ø¸´
peoplezz(½ð±Ò+5): лл²ÎÓë
anita*9Â¥
2023-09-15 21:33
»Ø¸´
Ó©»ð³æÖ®¹È12Â¥
2023-09-16 00:48
»Ø¸´
peoplezz(½ð±Ò+5): лл²ÎÓë
л ·¢×ÔСľ³æIOS¿Í»§¶Ë
¼Ù´ó¿Õ13Â¥
2023-09-16 09:43
»Ø¸´
peoplezz(½ð±Ò+5): лл²ÎÓë

68041614Â¥
2023-09-16 09:46
»Ø¸´
ÔÆÔÚÇàÌì15Â¥
2023-09-16 10:09
»Ø¸´
xishandian16Â¥
2023-09-16 10:50
»Ø¸´
peoplezz(½ð±Ò+5): лл²ÎÓë

xishandian17Â¥
2023-09-16 11:01
»Ø¸´

nono200918Â¥
2023-09-16 13:06
»Ø¸´
peoplezz(½ð±Ò+5): лл²ÎÓë
¡¤
Ôø¾²×º£a20Â¥
2023-09-16 15:43
»Ø¸´
peoplezz(½ð±Ò+5): лл²ÎÓë
hoikisu22Â¥
2023-09-16 18:04
»Ø¸´
peoplezz(½ð±Ò+5): лл²ÎÓë
×£¸£ ·¢×ÔСľ³æIOS¿Í»§¶Ë
ÐÀÕÜ-21123Â¥
2023-09-16 20:34
»Ø¸´
peoplezz(½ð±Ò+5): лл²ÎÓë
wukongbb25Â¥
2023-12-25 10:27
»Ø¸´















»Ø¸´´ËÂ¥
or overweight (BMI ¡Ý 27 kg/m ² ) adults with at least one weight related comorbidity and no diabetes compared with placebo.